Get the Stockscreener App
46.65
4.07%
-1.98
After Hours:
46.70
0.05
+0.11%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $46.65, with a volume of 19.73M.
It is down -4.07% in the last 24 hours and up +6.51% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$48.63
Open:
$48.27
24h Volume:
19.73M
Relative Volume:
1.35
Market Cap:
$94.95B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
15.75
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
-0.09%
1M Performance:
+6.51%
6M Performance:
+5.73%
1Y Performance:
-20.26%
1-Day Range:
$46.12
$48.37
1-Week Range:
$46.12
$49.99
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.65 | 99.00B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Is Bristol Myers Squibb Company stock a safe investment in uncertain markets2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
Good Life Advisors LLC Decreases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company (BRM) stock a contrarian opportunityMarket Trend Review & Safe Capital Preservation Plans - newser.com
Boston Partners Sells 3,760,655 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target - Finviz
Is Bristol Myers Squibb Company Celegne Contingent stock resilient in recession scenarios2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Police & Firemen s Retirement System of New Jersey Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Purchases 15,599 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Arvest Bank Trust Division - MarketBeat
Allianz SE Lowers Position in Bristol Myers Squibb Company $BMY - MarketBeat
Blood thinner failure thins BMS shares - The Pharma Letter
Bristol Myers, J&J halt heart drug trial after interim review - ETPharma.com
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? - Benzinga
Scotiabank Initiates Coverage on Bristol Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers, J&J’s new blood thinner fails first big test - BioPharma Dive
Bristol Myers, J&J stop blood clotting drug trial after interim review - Reuters
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy - Benzinga
Wealth Alliance LLC Cuts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Vestmark Advisory Solutions Inc. Trims Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb shares slide after halting key heart trial - MSN
Bristol-Myers Squibb stock falls after discontinuing acute coronary trial By Investing.com - Investing.com Canada
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com
Bristol Myers (BMY) Drops Following Phase 3 Trial Halt - GuruFocus
Bristol Myers falls after halting heart drug trial - TradingView
Bristol Myers Squibb discontinues Librexia ACS trial after review By Investing.com - Investing.com Canada
Bristol Myers Squibb Company $BMY Shares Sold by Nwam LLC - MarketBeat
Cherokee Insurance Co Takes $1.42 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Update on phase 3 Librexia ACS trial - MarketScreener
Candriam S.C.A. Sells 92,461 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Forsta AP Fonden Has $19.34 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Q&A: BioNTech co-founders discuss bispecific efforts, Bristol Myers deal, and the irony of competing with Pfizer - Endpoints News
Wealth Quarterback LLC Raises Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by KBC Group NV - MarketBeat
ProShare Advisors LLC Acquires 37,125 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb’s Oncology Strategy Gains Momentum - AD HOC NEWS
SCRI, BMS Expand Collaboration to Accelerate Patient Enrollment - Contract Pharma
Bristol Myers Squibb, Sarah Cannon expand oncology trial partnership - Investing.com
Does Bristol-Myers Squibb’s Rebound Signal Opportunity After Recent Biotech Acquisitions? - Yahoo Finance
Bristol Myers (NYSE: BMY) and SCRI broaden cancer trial access via Accelero at 200+ sites - Stock Titan
Zions Bancorporation National Association UT Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Evotec and BMS partnership yields IND approval - BioWorld MedTech
Evotec Receives $5 Million Milestone Payment From Bristol Myers Under Protein Degradation Partnership - MarketScreener
Bristol Myers Squibb Company $BMY Stake Boosted by denkapparat Operations GmbH - MarketBeat
Privacy notice center - Bristol Myers Squibb
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - ACCESS Newswire
Published on: 2025-11-12 00:59:26 - newser.com
Evotec gets USD 5 mln milestone payment from Bristol Myers Squibb - MarketScreener
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership - TradingView
Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating - Insider Monkey
Jim Cramer on Bristol-Myers: “I’m Backing off on It” - Insider Monkey
Bristol Myers Squibb Co. Stock Rises Monday, Still Underperforms Market - 富途牛牛
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):